Published in Blood Weekly, August 3rd, 2006
"B-CLL is characterized by the accumulation of long-lived CD5+ B lymphocytes. Several drugs currently used in the therapy of B-CLL act, at least partially, through activation of the p53 pathway," researchers in Spain reported.
"Recently, nongenotoxic small-molecule activators of p53, the nutlins, have been developed that inhibit p53-MDM2 binding," explained L. Collmulet and colleagues, University of Barcelona. "We have investigated the antitumor potential of nutlin-3 in B-CLL and find that it can activate the p53...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.